| 6 | 1/1 | 返回列表 |
| 查看: 1465 | 回復: 5 | |||
[交流]
輝瑞公司停止開發(fā)丙型肝炎藥物 已有5人參與
|
|
輝瑞制藥有限公司(Pfizer Inc., PFE, 簡稱:輝瑞公司)已停止丙型肝炎藥物的試驗開發(fā),退出了行業(yè)內(nèi)為引入新一代丙型肝炎治療藥而進行的激烈競爭。 該公司發(fā)言人Victoria Davis稱,公司在進行戰(zhàn)略評估后決定停止Filibuvir的開發(fā)。她表示,這一決定與安全問題無關。 該藥在停止開發(fā)前處于中期臨床試驗階段 |

至尊木蟲 (小有名氣)
|
Combination of filibuvir and peginterferon alfa-2a/ribavirin evaluated in HCV patients -------------------------------------------------------------------------------- Filibuvir (PF-00868554; Pfizer) has previously been evaluated as monotherapy in patients with hepatitis C (HCV), and whether the activity seen in that study could be enhanced by combination with peginterferon alfa-2a and ribavirin has now been assessed in a randomized, placebo-controlled trial. Patients with genotype 1 HCV (N = 35) were treated with filibuvir 200, 300 or 500 mg b.i.d. or placebo plus peginterferon alfa-2a 180 mcg/week and ribavirin 1000/1200 mg/day for 4 weeks, with the peginterferon/ribavirin treatment continuing for a further 44 weeks. During the 4-week filibuvir treatment period, the combination therapy was well tolerated, with headache, fatigue, insomnia and nausea the most common adverse events. Adverse events did not appear to be related to filibuvir dose. One serious adverse event related to treatment, elevated creatinine, was seen in the filibuvir 300 mg group. Mean reductions in HCV RNA at day 28 were -2.10, -4.46, -4.67 and -3.62 log10 IU/mL for the placebo and filibuvir 200, 300 and 500 mg groups, respectively. In these groups, 0, 60, 75 and 63% of patients achieved undetectable HCV RNA by week 4 (Jacobson, I. et al. 44th Annu Meet Eur Assoc Study Liver (EASL) (April 22-26, Copenhagen) 2009, Abst). |

木蟲 (著名寫手)
muchong

榮譽版主 (知名作家)
金蟲 (正式寫手)
| 6 | 1/1 | 返回列表 |
| 最具人氣熱帖推薦 [查看全部] | 作者 | 回/看 | 最后發(fā)表 | |
|---|---|---|---|---|
|
[考研] 0703化學調(diào)劑 +10 | 妮妮ninicgb 2026-03-15 | 14/700 |
|
|---|---|---|---|---|
|
[考研] 生物學調(diào)劑招人!。 +3 | 山海天嵐 2026-03-17 | 4/200 |
|
|
[考研] 0703化學調(diào)劑 ,六級已過,有科研經(jīng)歷 +12 | 曦熙兮 2026-03-15 | 12/600 |
|
|
[考研] 0703化學 305求調(diào)劑 +4 | FY_yy 2026-03-14 | 4/200 |
|
|
[考研] 材料專業(yè)求調(diào)劑 +5 | hanamiko 2026-03-18 | 5/250 |
|
|
[考研] 085601專碩,總分342求調(diào)劑,地區(qū)不限 +5 | share_joy 2026-03-16 | 5/250 |
|
|
[考研] 298-一志愿中國農(nóng)業(yè)大學-求調(diào)劑 +7 | 手機用戶 2026-03-17 | 7/350 |
|
|
[考研] 0703化學調(diào)劑 +3 | 妮妮ninicgb 2026-03-17 | 3/150 |
|
|
[考研] 268求調(diào)劑 +6 | 簡單點0 2026-03-17 | 6/300 |
|
|
[考研] 301求調(diào)劑 +4 | A_JiXing 2026-03-16 | 4/200 |
|
|
[考研] 考研化學學碩調(diào)劑,一志愿985 +4 | 張vvvv 2026-03-15 | 6/300 |
|
|
[考研] 085601求調(diào)劑 +4 | Du.11 2026-03-16 | 4/200 |
|
|
[考研] 274求調(diào)劑 +5 | 時間點 2026-03-13 | 5/250 |
|
|
[考研] 機械專碩325,尋找調(diào)劑院校 +3 | y9999 2026-03-15 | 5/250 |
|
|
[考研] 0854控制工程 359求調(diào)劑 可跨專業(yè) +3 | 626776879 2026-03-14 | 9/450 |
|
|
[考研] 326求調(diào)劑 +4 | 諾貝爾化學獎覬?/a> 2026-03-15 | 7/350 |
|
|
[考研] 318求調(diào)劑 +3 | Yanyali 2026-03-15 | 3/150 |
|
|
[考研] 0856求調(diào)劑 +3 | 劉夢微 2026-03-15 | 3/150 |
|
|
[考研] 求老師收留調(diào)劑 +4 | jiang姜66 2026-03-14 | 5/250 |
|
|
[考研] 085601材料工程315分求調(diào)劑 +3 | yang_0104 2026-03-15 | 3/150 |
|